NCT04314622View on ClinicalTrials.gov

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 14, 2020

Primary Completion Date

October 25, 2020

Study Completion Date

March 16, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Supaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

210000

The Affiliated Zhongda Hospital of Southeast University, Nanjing

All Listed Sponsors
collaborator

Shanghai 6th People's Hospital

OTHER

lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER

NCT04314622 - A Study of Supaglutide in Chinese Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter